AIM at Melanoma Foundation

Cancer Drug Parity Act Gains Strong Support from Leading Healthcare Organizations

Retrieved on: 
Wednesday, November 8, 2023
EBP, Insurance, Attention, ONS, Act, AIM, Public policy, International Myeloma Foundation, IV, Congress, House, Legislation, Face, IMF, RN, Multiple myeloma, CLL, AIM at Melanoma Foundation, Disease, Melanoma, DNP, ACS, Representative, Parity, Oncology Nursing Society, Association of American Cancer Institutes, Cancer, American Cancer Society Cancer Action Network, Oral cancer, Patient, ASCO, Lymphoma, Health insurance, Pharmaceutical industry, Nursing, Dietary supplement

The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families.

Key Points: 
  • The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families.
  • The Cancer Drug Parity Act would put the needs of patients first to ensure that patients, along with their healthcare providers, can choose the treatment option they deem is most appropriate”.
  • ONS is proud to support the Cancer Drug Parity Act and commends the bill’s sponsors for their leadership in ensuring parity for oral cancer treatments.”
    Recognizing the pressing need for equitable access to cancer treatments, Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), emphasized the critical issue of disparities in cost-sharing for oral chemotherapy medications.
  • For more information on the Cancer Drug Parity Act and its potential impact on cancer care, please visit https://www.access2cancercare.org/ .

RDK Melanoma Foundation and Astreea Team Up to Strike Out Sunburns at Citizens Bank Ballpark

Retrieved on: 
Thursday, February 3, 2022
Stadium, RDK, Philadelphia Phillies, AIM at Melanoma Foundation, XXL, Skin cancer, Foundation, Partnership, Student, Education, Sam's Club, Attention, SPF, Maintenance, Cosmetics, Melanoma

PHILADELPHIA, Feb. 3, 2022 /PRNewswire/ --The Richard David Kann (RDK) Melanoma Foundation is partnering with Astreea to offer fans free sunscreen at Citizens Bank Ballpark, home of the Philadelphia Phillies.

Key Points: 
  • PHILADELPHIA, Feb. 3, 2022 /PRNewswire/ --The Richard David Kann (RDK) Melanoma Foundation is partnering with Astreea to offer fans free sunscreen at Citizens Bank Ballpark, home of the Philadelphia Phillies.
  • The RDK Melanoma Foundation's mission is to save lives through education on the prevention and early detection of skin cancer, specifically Melanoma.
  • "The Phillies, myself, and the Richard David Kann Melanoma Foundation want to hit a home run with this project!"
  • Astreea dispensers are durable, hygienic, and weatherproof, making them perfect for use at Citizens Bank Ballpark.

Global Non-Melanoma Skin Cancer Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Oncology, Medicine, Health, Cancer, Melanoma, Medical education, Skin cancer, Uveal melanoma, AIM at Melanoma Foundation

b'The "Global Non-Melanoma Skin Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Melanoma Skin Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Melanoma Skin Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Non-Melanoma Skin Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Melanoma Skin Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Melanoma Skin Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Non-Melanoma Skin Cancer patients, history of the disease at the population level (Non-Melanoma Skin Cancer prevalence, Non-Melanoma Skin Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nNon-Melanoma Skin Cancer patient flow: Non-Melanoma Skin Cancer prevalence, diagnosed, and drug-treated patients\nDemographics: Non-Melanoma Skin Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Non-Melanoma Skin Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Non-Melanoma Skin Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Non-Melanoma Skin Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005208/en/\n'

2021 Global Melanoma Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, Oncology, Cancer, Melanoma, Medical education, Health, Medicine, AIM at Melanoma Foundation

b'The "Global Melanoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Melanoma Epidemiology and Patient Flow Analysis - 2021, provides Melanoma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Melanoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Melanoma Epidemiology and Patient Flow Analysis - 2021, provides Melanoma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Melanoma patients, history of the disease at the population level (Melanoma prevalence, Melanoma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Melanoma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Melanoma market sizing, assessing market potential, and developing drug forecast models\nIdentify Melanoma patients segments through age groups, gender, and disease sub-types\n'

The Melanoma Research Foundation Identifies Three Key Battlegrounds as Research Shows Skin Cancer Reaches Epidemic Proportions

Retrieved on: 
Friday, May 1, 2020
RTT, Sun tanning, Health, Cancer, Melanoma, Medical education, Neoplasms, Skin cancer, AIM at Melanoma Foundation

In the '2020 Melanoma Skin Cancer Report: Stemming the Global Epidemic,' the Global Coalition for Melanoma Patient Advocacy and Euromelanoma identify three key battlegrounds for fighting melanoma: the need to improve public awareness of melanoma risk factors; reducing intentional tanning; and making skin self-examinations a regular habit.

Key Points: 
  • In the '2020 Melanoma Skin Cancer Report: Stemming the Global Epidemic,' the Global Coalition for Melanoma Patient Advocacy and Euromelanoma identify three key battlegrounds for fighting melanoma: the need to improve public awareness of melanoma risk factors; reducing intentional tanning; and making skin self-examinations a regular habit.
  • Globally, the incidence of melanoma was found to have reached epidemic proportions.
  • "In the '2020 Melanoma Skin Cancer Report' we set out the definitive actions needed to change mindsets and behaviors.
  • The publication of the '2020 Melanoma Skin Cancer Report: Stemming the Global Epidemic' coincides with the launch of a public awareness campaign by the Global Coalition for Melanoma Patient Advocacy and Euromelanoma.

AIM At Melanoma And The Mollie Biggane Melanoma Foundation Offer New Education Brochure

Retrieved on: 
Wednesday, February 26, 2020
Melanoma, RTT, Health, Medicine, Organ systems, Cancer, AIM at Melanoma Foundation, Skin cancer, Uveal melanoma, James A. Schlipmann Melanoma Cancer Foundation

GARDEN CITY, N.Y., Feb. 26, 2020 /PRNewswire/ --The Mollie Biggane Melanoma Foundation (Garden City, New York) and the AIM at Melanoma Foundation (San Rafael, California) have partnered to create and produce "What is Ocular Melanoma?"

Key Points: 
  • GARDEN CITY, N.Y., Feb. 26, 2020 /PRNewswire/ --The Mollie Biggane Melanoma Foundation (Garden City, New York) and the AIM at Melanoma Foundation (San Rafael, California) have partnered to create and produce "What is Ocular Melanoma?"
  • AIM at Melanoma provides education, connection to resources and opportunities for meaningful engagement to help patients and caregviers/families better face the challenges of melanoma.
  • ABOUT THE MOLLIE BIGGANE MELANOMA FOUNDATION: Founded in 2000, after Mollie's death at twenty of metastatic melanoma, the foundation increases awareness for melanoma prevention, provides information and services on skin cancer detection and supports melanoma patients through education of the latest treatments.
  • The Mollie Biggane Melanoma Foundation coordinates and produces a multitude of educational programs in schools, local governments and hospital systems.

Melanoma Research Alliance Announces Nine Research Awards in Inaugural Class of Dermatology Fellows

Retrieved on: 
Wednesday, September 4, 2019
General Health, Philanthropy, Fund Raising, Foundation, Family, Science, Other Philanthropy, Consumer, Other Science, Research, Health, Cancer, Melanoma, RTT, Academic journals, Health, Medicine, AIM at Melanoma Foundation

In recognition of the critical role dermatologists can play in the prevention and early detection of melanoma, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced the inaugural cohort of nine dermatology research fellows.

Key Points: 
  • In recognition of the critical role dermatologists can play in the prevention and early detection of melanoma, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced the inaugural cohort of nine dermatology research fellows.
  • The grants will support innovative research and demonstration projects to advance melanoma prevention, detection, staging, and early interventional treatments.
  • By investing in early career dermatologists, the program also aims to build a pipeline of promising scientists who specialize in melanoma.
  • Research supported by MRA has helped usher in a new era in melanoma treatment with 12 new FDA approved options this decade.

Media Advisory - Save Your Skin Launches Inaugural “Move For Melanoma” Challenge Benefiting Skin Cancer Patients Across Canada

Retrieved on: 
Friday, August 30, 2019
RTT, Health, Neoplasms, Medicine, Sun tanning, Melanoma, Skin cancer, Uveal melanoma, Cancer, Colorado Melanoma Foundation, AIM at Melanoma Foundation

Kathleen Barnard, President and Founder of Save Your Skin Foundation, and also a stage four-melanoma survivor, is also available for interview.

Key Points: 
  • Kathleen Barnard, President and Founder of Save Your Skin Foundation, and also a stage four-melanoma survivor, is also available for interview.
  • For interview requests or further information, contact:
    Save Your Skin Foundation (SYSF) is a national patient-led not-for-profit group dedicated to the fight against non-melanoma skin cancers, melanoma and ocular melanoma through nationwide education, advocacy, and awareness initiatives.Save Your Skin Foundation is committed to playing anactive role in reducing the incidence of skin cancer in Canada, and to providing compassionate support for all Canadians living with skin cancers.

Non-Melanoma Skin Cancer Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stage, Drug Mechanism Class, Company - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 13, 2019
Health, Clinical trials, Oncology, Pharmaceutical, Health, RTT, Medicine, Melanoma, Skin cancer, Cancer, Clinical trial, AIM at Melanoma Foundation, CancerVax

The "Global Non-Melanoma Skin Cancer Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Melanoma Skin Cancer Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Non-Melanoma Skin Cancer Pipeline Highlights - 2019 provides the most up-to-date information on key pipeline products in the global Non-Melanoma Skin Cancer market.
  • It covers emerging therapies for Non-Melanoma Skin Cancer in active clinical development stages including early and late stage clinical trials.
  • The report provides Non-Melanoma Skin Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

World Melanoma Day 2019 - As melanoma rates continue to rise in Canada, new survey shows some worrisome trends in sun-safe behaviours among Canadians

Retrieved on: 
Monday, May 13, 2019
RTT, Melanoma, Sun tanning, Health, Cancer, Medical education, Neoplasms, Skin cancer, Skin cancer in Australia, AIM at Melanoma Foundation

The latest CDA Sun Safe Behaviour Survey shows that Canadians continue to have misconceptions about certain "sun smart" practices.

Key Points: 
  • The latest CDA Sun Safe Behaviour Survey shows that Canadians continue to have misconceptions about certain "sun smart" practices.
  • World Melanoma Day is marked annually around the globe on the second Monday in May and May is recognized as Melanoma Awareness Month.
  • From 1992 to 2013, the incidence rates of melanoma went up 2.1% per year for men, and 2.0% for women.
  • According to the Canadian Cancer Society, in 2017, an estimated 7,200 Canadians were diagnosed with melanoma skin cancer and 1,250 Canadians died from the disease.